GSTM1 and anemia (phenotype): Although these subgroups of interest were selected primarily to evaluate the anemia-related benefits of momelotinib versus BAT/ruxolitinib, rates of splenic response [Hb < 100 g/L: 6 (9.1%) vs. 2 (5.1%); non-TI: 7 (9.7%) vs. 1 (3.0%)] and symptom response [Hb < 100 g/L: 21 (32.3%) vs. 1 (2.6%); non-TI: 21 (29.2%) vs. 0] at week 24 were also higher with momelotinib (Fig. 3).